DK3204022T3 - Placenta-afledte adhærente celle-exosomer og anvendelser deraf - Google Patents

Placenta-afledte adhærente celle-exosomer og anvendelser deraf Download PDF

Info

Publication number
DK3204022T3
DK3204022T3 DK15849339.5T DK15849339T DK3204022T3 DK 3204022 T3 DK3204022 T3 DK 3204022T3 DK 15849339 T DK15849339 T DK 15849339T DK 3204022 T3 DK3204022 T3 DK 3204022T3
Authority
DK
Denmark
Prior art keywords
placenta
adherent cell
derived adherent
cell exosomes
exosomes
Prior art date
Application number
DK15849339.5T
Other languages
Danish (da)
English (en)
Inventor
Eric Law
Andrew Morschauser
Aleksandar Francki
Jennifer Paredes
Kathy E Karasiewicz-Mendez
Allan Reduta
Ivana Djuretic
Vladimir Jankovic
Original Assignee
Celularity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55653751&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3204022(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celularity Inc filed Critical Celularity Inc
Application granted granted Critical
Publication of DK3204022T3 publication Critical patent/DK3204022T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
    • C12N2502/025—Coculture with; Conditioned medium produced by embryonic cells extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK15849339.5T 2014-10-09 2015-10-08 Placenta-afledte adhærente celle-exosomer og anvendelser deraf DK3204022T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462062046P 2014-10-09 2014-10-09
PCT/US2015/054629 WO2016057755A1 (en) 2014-10-09 2015-10-08 Placenta-derived adherent cell exosomes and uses thereof

Publications (1)

Publication Number Publication Date
DK3204022T3 true DK3204022T3 (da) 2021-03-08

Family

ID=55653751

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15849339.5T DK3204022T3 (da) 2014-10-09 2015-10-08 Placenta-afledte adhærente celle-exosomer og anvendelser deraf

Country Status (8)

Country Link
US (3) US20170252379A1 (enExample)
EP (1) EP3204022B1 (enExample)
JP (3) JP2017536096A (enExample)
CN (2) CN107106615A (enExample)
AU (2) AU2015330855A1 (enExample)
CA (1) CA2964114A1 (enExample)
DK (1) DK3204022T3 (enExample)
WO (1) WO2016057755A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107250148B (zh) 2014-12-03 2021-04-16 安捷伦科技有限公司 具有化学修饰的指导rna
ES2884838T3 (es) 2015-04-06 2021-12-13 Univ Leland Stanford Junior ARN guía químicamente modificados para la regulación génica mediada por CRISPR/CAS
CA2988585A1 (en) 2015-06-10 2016-12-15 Raghu Kalluri Use of exosomes for the treatment of disease
CN109477072A (zh) * 2016-05-16 2019-03-15 埃克森蒂姆生物技术公司 间充质干细胞及其用于治疗肌肉损伤和肌肉相关疾病的用途
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
US11576872B2 (en) 2017-05-08 2023-02-14 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
WO2018208702A1 (en) * 2017-05-09 2018-11-15 Saint Louis University Treatment of cancer and infectious diseases with natural killer (nk) cell-derived exosomes
AU2018270408A1 (en) * 2017-05-16 2019-12-12 Exostem Biotec Ltd. Methods of inhibiting aging and treating aging-related disorders
US20180340945A1 (en) * 2017-05-24 2018-11-29 Nanosomix, Inc. Detection of biomarkers on vesicles for the diagnosis and prognosis of diseases and disorders
KR102109950B1 (ko) * 2017-06-02 2020-05-12 (주)엑솔런스바이오테크놀로지 체외충격파를 이용한 세포외소포체 내로의 표적물질 전달방법
BR112020003354A2 (pt) 2017-08-25 2020-08-18 Codiak Biosciences, Inc. preparação de exossomas terapêuticos usando proteínas de membrana
KR102335710B1 (ko) * 2017-10-31 2021-12-07 (주)아모레퍼시픽 유산균 유래의 세포밖 베지클을 포함하는 면역조절용 조성물
GB201718681D0 (en) * 2017-11-13 2017-12-27 Evox Therapeutics Ltd Protein engineered extracellular vesicles
AU2018370157A1 (en) * 2017-11-16 2020-05-28 Celularity Inc. Cultivation of placenta to isolate exosomes
US12036325B2 (en) 2017-12-14 2024-07-16 Mayo Foundation For Medical Education And Research Purified exosome products, method of making, and methods of using
AU2018394238A1 (en) 2017-12-28 2020-06-18 Lonza Sales Ag Exosomes for immuno-oncology and anti-inflammatory therapy
CN112384200A (zh) * 2018-01-30 2021-02-19 希斯托金公司 低氧条件下培养的细胞衍生的胞外囊泡及其用途
WO2019241910A1 (zh) * 2018-06-19 2019-12-26 中国医学科学院阜外医院 基于药物预处理的间充质干细胞来源外泌体的制备方法
CA3107386A1 (en) * 2018-07-24 2020-01-30 Mayo Foundation For Medical Education And Research Compositions and methods involving transforming extracellular vesicles
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN109554341B (zh) * 2018-12-18 2021-11-19 深圳先进技术研究院 无创超声处理细胞在制备外泌体中的应用、外泌体及其制备方法和应用
CN110093274B (zh) * 2019-05-13 2020-08-11 山东大学 一种增加细胞产生的细胞外囊泡数量的挤压装置及其应用
CN114302731A (zh) * 2019-06-19 2022-04-08 细胞结构公司 用于治疗疾病的外泌体
KR20220167294A (ko) * 2020-04-14 2022-12-20 (주)녹십자웰빙 태반 유래 물질을 포함하는 항바이러스 조성물
KR20220030552A (ko) * 2020-09-03 2022-03-11 (주)녹십자웰빙 태반 유래 엑소좀을 포함하는 간세포 증식 또는 항염증 효능 조성물
US11884915B2 (en) 2021-09-10 2024-01-30 Agilent Technologies, Inc. Guide RNAs with chemical modification for prime editing
WO2024102969A1 (en) * 2022-11-10 2024-05-16 Board Of Regents, The University Of Texas System Use of fecal derivatives and fecal derived extracellular vesicles to enhance immunity

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ527849A (en) 2001-02-14 2006-09-29 Anthrogenesis Corp Post-partum mammalian placenta, its use and placental stem cells therefrom
DK2471904T3 (en) 2005-12-29 2019-02-18 Celularity Inc Placenta stem cell populations
JP5950577B2 (ja) 2008-08-20 2016-07-13 アンスロジェネシス コーポレーション 単離胎盤細胞を使用した脳卒中の治療
CN102282249A (zh) * 2008-09-02 2011-12-14 普拉里斯坦有限公司 来自胎盘组织的粘附细胞及其在治疗中的用途
EP3181705A1 (en) * 2008-11-12 2017-06-21 Caris Life Sciences Switzerland Holdings GmbH Methods and systems of using exosomes for determining phenotypes
FR2950360B1 (fr) * 2009-09-22 2011-11-25 Centre Nat Rech Scient Procede d'imagerie cellulaire pour la visualisation de la biogenese des microarns dans les cellules
TW201703777A (zh) * 2010-04-07 2017-02-01 安瑟吉納西斯公司 利用胎盤幹細胞之血管新生
WO2012135805A2 (en) * 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
BR112013032232A2 (pt) * 2011-06-16 2016-09-20 Caris Life Sciences Switzerland Holdings S A R L método de caracterização de câncer através do uso de biomarcador de ácido nucleico
JP6029112B2 (ja) * 2011-12-22 2016-11-24 テオリアサイエンス株式会社 エクソソームの分析方法、エクソソーム分析用試薬およびエクソソーム分析装置
US9427450B2 (en) * 2012-01-31 2016-08-30 Xon Cells, Inc. Therapeutic immune modulation by stem cell secreted exosomes
WO2014022852A1 (en) * 2012-08-03 2014-02-06 Aptamir Therapeutics, Inc. Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
US9828603B2 (en) * 2012-08-13 2017-11-28 Cedars Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
KR20150105956A (ko) * 2012-12-12 2015-09-18 더 브로드 인스티튜트, 인코퍼레이티드 서열 조작 및 치료적 적용을 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화
WO2014100434A1 (en) * 2012-12-19 2014-06-26 Caris Science, Inc. Compositions and methods for aptamer screening
EP3608022A1 (en) * 2013-03-15 2020-02-12 The Trustees of Princeton University Methods and devices for high throughput purification

Also Published As

Publication number Publication date
AU2015330855A1 (en) 2017-04-27
JP2021040635A (ja) 2021-03-18
WO2016057755A1 (en) 2016-04-14
EP3204022A1 (en) 2017-08-16
JP2017536096A (ja) 2017-12-07
CN116731958A (zh) 2023-09-12
US20170252379A1 (en) 2017-09-07
AU2021204332A1 (en) 2021-07-22
US20220241347A1 (en) 2022-08-04
JP2023011580A (ja) 2023-01-24
US11173182B1 (en) 2021-11-16
CN107106615A (zh) 2017-08-29
EP3204022A4 (en) 2018-06-13
CA2964114A1 (en) 2016-04-14
EP3204022B1 (en) 2020-12-02

Similar Documents

Publication Publication Date Title
DK3204022T3 (da) Placenta-afledte adhærente celle-exosomer og anvendelser deraf
DK3597742T3 (da) Car-udtrykkende vektor og car-udtrykkende t-celler
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
ZA201605858B (en) Novel polysaccharide and uses thereof
DK3212255T3 (da) Selvorienterende sprøjte og sprøjtegrænseflade
HUE046262T2 (hu) Sejt
DK3480213T3 (da) Syntac-polypeptider og anvendelser deraf
IL247014A0 (en) 6-heteroaryloxy and 6-aryloxy-quinoline-2-carboxamides and their use
IL249970B (en) Gamma delta t cells and uses thereof
GB201413355D0 (en) Compositons and methods
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
DK3101760T3 (da) Opladningsfremgangsmåde og system
DK3138048T3 (da) Kodede celler og cellearrays
DK3131577T3 (da) Modificerede værtsceller og anvendelser deraf
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3337506T3 (da) Kombinationer og anvendelser deraf
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
SG11201610514SA (en) Bioreactor and uses thereof
DK3101770T3 (da) Strømadapter og terminal
DK3180335T3 (da) Cytokrom-p450-inhibitorer og anvendelser deraf
DK3107376T3 (da) Svampelinje b12998-s39 og fremgangsmåder dertil og anvendelser herfor
GB201408091D0 (en) Methods and uses
GB201616232D0 (en) Novel cell line and uses thereof